| Product Code: ETC343141 | Publication Date: Aug 2022 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The United States continues to rely on key exporters such as India, Canada, Mexico, UK, and Switzerland for pulmonary/respiratory drug delivery imports in 2024. With a moderate Herfindahl-Hirschman Index (HHI) concentration, the market remains competitive. The compound annual growth rate (CAGR) from 2020 to 2024 stands at 1.49%, indicating steady growth. Notably, there was a notable growth rate of 6.04% from 2023 to 2024, showcasing potential opportunities for further expansion in the coming years.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Pulmonary/ Respiratory Drug Delivery Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Pulmonary/ Respiratory Drug Delivery Market - Industry Life Cycle |
3.4 United States (US) Pulmonary/ Respiratory Drug Delivery Market - Porter's Five Forces |
3.5 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume Share, By Formulations, 2021 & 2031F |
3.6 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume Share, By Canister Type, 2021 & 2031F |
3.7 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume Share, By Applications, 2021 & 2031F |
3.8 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 United States (US) Pulmonary/ Respiratory Drug Delivery Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of respiratory diseases such as asthma, COPD, and cystic fibrosis |
4.2.2 Technological advancements in drug delivery devices for respiratory conditions |
4.2.3 Growing geriatric population susceptible to respiratory illnesses |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of respiratory drug delivery devices |
4.3.2 High cost associated with development and commercialization of innovative respiratory drug delivery technologies |
4.3.3 Limited accessibility to advanced respiratory drug delivery devices in certain regions of the US |
5 United States (US) Pulmonary/ Respiratory Drug Delivery Market Trends |
6 United States (US) Pulmonary/ Respiratory Drug Delivery Market, By Types |
6.1 United States (US) Pulmonary/ Respiratory Drug Delivery Market, By Formulations |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Formulations, 2021 - 2031F |
6.1.3 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Type, 2021 - 2031F |
6.1.4 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Device Type, 2021 - 2031F |
6.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market, By Canister Type |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Plain Canister, 2021 - 2031F |
6.2.3 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Coated Canister, 2021 - 2031F |
6.3 United States (US) Pulmonary/ Respiratory Drug Delivery Market, By Applications |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Asthma, 2021 - 2031F |
6.3.3 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By COPD, 2021 - 2031F |
6.3.4 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Cystic Fibrosis, 2021 - 2031F |
6.4 United States (US) Pulmonary/ Respiratory Drug Delivery Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Hospitals & Clinics, 2021 - 2031F |
6.4.3 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenues & Volume, By Homecare settings, 2021 - 2031F |
7 United States (US) Pulmonary/ Respiratory Drug Delivery Market Import-Export Trade Statistics |
7.1 United States (US) Pulmonary/ Respiratory Drug Delivery Market Export to Major Countries |
7.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Imports from Major Countries |
8 United States (US) Pulmonary/ Respiratory Drug Delivery Market Key Performance Indicators |
8.1 Average time to market for new respiratory drug delivery devices |
8.2 Adoption rate of innovative drug delivery technologies in respiratory care settings |
8.3 Patient adherence rates to prescribed respiratory medications |
8.4 Number of clinical trials for novel respiratory drug delivery devices |
8.5 Frequency of respiratory exacerbations in patients using different drug delivery methods |
9 United States (US) Pulmonary/ Respiratory Drug Delivery Market - Opportunity Assessment |
9.1 United States (US) Pulmonary/ Respiratory Drug Delivery Market Opportunity Assessment, By Formulations, 2021 & 2031F |
9.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Opportunity Assessment, By Canister Type, 2021 & 2031F |
9.3 United States (US) Pulmonary/ Respiratory Drug Delivery Market Opportunity Assessment, By Applications, 2021 & 2031F |
9.4 United States (US) Pulmonary/ Respiratory Drug Delivery Market Opportunity Assessment, By End User, 2021 & 2031F |
10 United States (US) Pulmonary/ Respiratory Drug Delivery Market - Competitive Landscape |
10.1 United States (US) Pulmonary/ Respiratory Drug Delivery Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Pulmonary/ Respiratory Drug Delivery Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |